Skip to main content
Equibles

UBS Group AG

Position in GILD — Gilead Sciences, Inc.

CIK 1610520 ZURICH, V8
Back to GILD Full portfolio

Position in GILD

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$547,754,202
-$38,903,597 QoQ
Shares Held
3,930,216
-17.8% QoQ
Ownership
0.317%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 72.85808210032222.ToString("F0")% Shared 0.ToString("F0")% None 27.141917899677782.ToString("F0")%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Mar 31, 2026
CallValue
$19,287,135
CallShares
138,388
PutValue
$10,522,435
PutShares
75,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

UBS Group AG holds $15,459,459,109 across 21 Drug Manufacturers - General names. GILD ranks #7 (3.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 4,043,568 $3,719,152,536
2 ABBV
AbbVie Inc.
 14,051,196 $3,055,994,614
3 JNJ
Johnson & Johnson
 10,209,327 $2,495,567,886
4 MRK
Merck & Co., Inc.
 13,933,630 $1,676,076,347
5 AZN
Astrazeneca PLC
 5,981,411 $1,179,653,872
6 AMGN
Amgen Inc
 3,148,040 $1,107,637,870
7 GILD
Gilead Sciences, Inc.
This page 		3,930,216 $547,754,202
8 PFE
Pfizer Inc
 17,609,150 $494,464,929

All Filings in GILD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $10,522,435 75,500
2026-03-31 $547,754,202 3,930,216
2026-03-31 $19,287,135 138,388
2025-12-31 $41,522,942 338,300
2025-12-31 $586,657,799 4,779,679
2025-12-31 $29,468,401 240,088
2025-09-30 $571,393,035 5,147,685
2025-09-30 $41,436,300 373,300
2025-09-30 $34,741,668 312,988
2025-06-30 $40,755,812 367,600
2025-06-30 $505,658,333 4,560,822
2025-06-30 $31,951,403 288,188
2025-03-31 $60,555,181 540,430
2025-03-31 $518,368,171 4,626,222
2025-03-31 $63,117,765 563,300
2024-12-31 $451,099,976 4,883,620
2024-12-31 $94,494,510 1,023,000
2024-12-31 $59,143,402 640,288
2024-09-30 $58,520,320 698,000
2024-09-30 $346,923,459 4,137,923
2024-09-30 $42,782,545 510,288
2024-06-30 $308,521,669 4,496,745
2024-06-30 $28,012,639 408,288
2024-06-30 $36,479,937 531,700
2024-03-31 $308,669,200 4,213,914
2024-03-31 $25,725,400 351,200
2024-03-31 $45,451,625 620,500
2023-12-31 $47,949,819 591,900
2023-12-31 $105,240,091 1,299,100
2023-12-31 $288,096,668 3,556,310
2023-09-30 $94,956,474 1,267,100
2023-09-30 $232,682,179 3,104,913
2023-09-30 $46,440,318 619,700
2023-06-30 $42,334,551 549,300
2023-06-30 $258,722,677 3,356,983
2023-06-30 $81,486,111 1,057,300
2023-03-31 $173,222,938 2,087,778
2023-03-31 $63,530,129 765,700
2023-03-31 $115,286,815 1,389,500
2022-12-31 $164,775,768 1,919,345
2022-12-31 $61,365,580 714,800
2022-12-31 $243,035,510 2,830,932
2022-09-30 $137,380,173 2,226,944
2022-09-30 $22,819,131 369,900
2022-09-30 $68,426,548 1,109,200
2022-06-30 $16,126,229 260,900
2022-06-30 $175,607,213 2,841,081
2022-06-30 $54,751,298 885,800
2022-03-31 $84,115,805 1,414,900
2022-03-31 $35,687,835 600,300

Report a Problem

Category
Description
Email (optional, for follow-up)